The R262K substitution combined with H51Y in HIV-1 subtype B integrase confers low-level resistance against dolutegravir

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 310-316

  Cutillas, Vincent ^a,b   Mesplede, Thibault ^a   Anstett, Kaitlin ^a,b   Hassounah, Said ^a,b   Wainberga, Mark A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOLUTEGRAVIR; ENZYME; INTEGRASE; PROTEIN H51Y; PROTEIN R262K; UNCLASSIFIED DRUG; FUSED HETEROCYCLIC RINGS; INTEGRASE INHIBITOR; P31 INTEGRASE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; VIRUS DNA;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DNA BINDING; ENZYME ACTIVITY; ENZYME KINETICS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE B; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE; TISSUE CULTURE; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS REPLICATION; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; BINDING SITE; CHEMISTRY; COMPUTER SIMULATION; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; METABOLISM; MOLECULAR MODEL; PROTEIN CONFORMATION; VIROLOGY;

AMINO ACID SUBSTITUTION; BINDING SITES; COMPUTER SIMULATION; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HEK293 CELLS; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION;

EID: 84920131765     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04274-14     Document Type: Article

References (34)

1. Quashie PK, Mesplede T, Wainberg MA. 2013. HIV drug resistance and the advent of integrase inhibitors. Curr Infect Dis Rep 15:85-100. http: //dx.doi.org/10.1007/s11908-012-0305-1.
2. Wainberg MA, Mesplede T, Quashie PK. 2012. The development of novel HIV integrase inhibitors and the problem of drug resistance. Curr Opin Virol 2:656-662. http://dx.doi.org/10.1016/j.coviro.2012.08.007.
3. Hightower KE, Wang R, Deanda F, Johns BA, Weaver K, Shen Y, Tomberlin GH, Carter HL, III, Broderick T, Sigethy S, Seki T, Kobayashi M, Underwood MR. 2011. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 55:4552-4559. http://dx.doi.org /10.1128/AAC.00157-11.
4. Ballantyne AD, Perry CM. 2013. Dolutegravir: first global approval. Drugs 73:1627-1637. http://dx.doi.org/10.1007/s40265-013-0121-4.
5. Craigie R. 2001. HIV integrase, a brief overview from chemistry to therapeutics. J Biol Chem 276:23213-23216. http://dx.doi.org/10.1074/jbc .R100027200.
6. Wainberg MA, Mesplede T, Raffi F. 2013. What if HIV were unable to develop resistance against a new therapeutic agent? BMC Med 11:249. http://dx.doi.org/10.1186/1741-7015-11-249.
7. Mesplede T, Quashie PK, Wainberg MA. 2012. Resistance to HIV integrase inhibitors. Curr Opin HIV AIDS 7:401-408. http://dx.doi.org/10 .1097/COH.0b013e328356db89.
8. Quashie PK, Mesplede T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, Underwood MR, Wainberg MA. 2012. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the sec-ond-generation integrase strand transfer inhibitor dolutegravir. J Virol 86:2696-2705. http://dx.doi.org/10.1128/JVI.06591-11.
9. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S. 2013. Dolutegravir versus raltegravir in antiretroviral-experienced, inte-grase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 382:700-708. http://dx.doi.org/10.1016/S0140-6736(13)61221-0.
10. Mesplede T, Quashie PK, Osman N, Han Y, Singhroy DN, Lie Y, Petropoulos CJ, Huang W, Wainberg MA. 2013. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 10: 22. http://dx.doi.org/10.1186/1742-4690-10-22.
11. Oliveira M, Mesplede T, Quashie PK, Moisi D, Wainberg MA. 2014. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS 28: 813-819. http://dx.doi.org/10.1097/QAD.0000000000000199.
12. Canducci F, Sampaolo M, Marinozzi MC, Boeri E, Spagnuolo V, Galli A, Castagna A, Lazzarin A, Clementi M, Gianotti N. 2009. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS 23:455-460. http://dx.doi.org/10.1097/QAD.0b013e328323da60.
13. Lutzke RA, Plasterk RH. 1998. Structure-based mutational analysis of the C-terminal DNA-binding domain of human immunodeficiency virus type 1 integrase: critical residues for protein oligomerization and DNA binding. J Virol 72:4841-4848.
14. Quashie PK, Mesplede T, Han YS, Veres T, Osman N, Hassounah S, Sloan RD, Xu HT, Wainberg MA. 2013. Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase. Antimicrob Agents Chemother 57:6223-6235. http://dx.doi.org /10.1128/AAC.01835-13. (Erratum, 58:633, 2014, http://dx.doi.org/10.1128 /AAC.02534-13.)
15. Bar-Magen T, Donahue DA, McDonough EI, Kuhl BD, Faltenbacher VH, Xu H, Michaud V, Sloan RD, Wainberg MA. 2010. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays. AIDS 24:2171-2179. http://dx .doi.org/10.1097/QAD.0b013e32833cf265.
16. Walker JM. 2005. The proteomics protocols handbook. Humana Press, Totowa, NJ.
17. Han YS, Xiao WL, Quashie PK, Mesplede T, Xu H, Deprez E, Delelis O, Pu JX, Sun HD, Wainberg MA. 2013. Development of a fluorescencebased HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors. Antiviral Res 98:441-448. http://dx.doi.org /10.1016/j.antiviral.2013.04.001.
18. Han YS, Quashie P, Mesplede T, Xu HT, Mekhssian K, Fenwick C, Wainberg MA. 2012. A high-throughput assay for HIV-1 integrase 3=-processing activity using time-resolved fluorescence. J Virol Methods 184: 34-40. http://dx.doi.org/10.1016/j.jviromet.2012.05.003.
19. Xu HT, Asahchop EL, Oliveira M, Quashie PK, Quan Y, Brenner BG, Wainberg MA. 2011. Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J Virol 85:11300-11308. http://dx.doi.org/10.1128/JVI.05584-11.
20. Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P. 2010. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464:232-236. http://dx.doi.org/10.1038/nature08784.
21. Hare S, Maertens GN, Cherepanov P. 2012. 3=-processing and strand transfer catalysed by retroviral integrase in crystallo. EMBO J 31:3020-3028. http://dx.doi.org/10.1038/emboj.2012.118.
22. Zhang Y. 2008. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 9:40. http://dx.doi.org/10.1186/1471-2105-9-40.
23. Roy A, Kucukural A, Zhang Y. 2010. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 5:725-738. http://dx.doi.org/10.1038/nprot.2010.5.
24. Webb B, Sali A. 2014. Protein structure modeling with MODELLER. Methods Mol Biol 1137:1-15. http://dx.doi.org/10.1007/978-1-4939-0366-5-1.
25. Eswar N, Webb B, Marti-Renom MA, Madhusudhan MS, Eramian D, Shen MY, Pieper U, Sali A. 2007. Comparative protein structure modeling using MODELLER. Curr Protoc Protein Sci Chapter 2:Unit 2.9. http: //dx.doi.org/10.1002/0471140864.ps0209s50.
26. Sheik SS, Sundararajan P, Hussain AS, Sekar K. 2002. Ramachandran plot on the web. Bioinformatics 18:1548-1549. http://dx.doi.org/10.1093 /bioinformatics/18.11.1548.
27. Kolaskar AS, Sawant S. 1996. Prediction of conformational states of amino acids using a Ramachandran plot. Int J Pept Protein Res 47: 110-116.
28. Prlic A, Bliven S, Rose PW, Bluhm WF, Bizon C, Godzik A, Bourne PE. 2010. Pre-calculated protein structure alignments at the RCSB PDB website. Bioinformatics 26: 2983-2985. http://dx.doi.org/10.1093 /bioinformatics/btq572.
29. Bhuyan MS, Gao X. 2011. A protein-dependent side-chain rotamer library. BMC Bioinformatics 12(Suppl 14):S10. http://dx.doi.org/10.1186 /1471-2105-12-S14-S10.
30. Zembower DE, Liao S, Flavin MT, Xu ZQ, Stup TL, Buckheit RW, Jr, Khilevich A, Mar AA, Sheinkman AK. 1997. Structural analogues of the calanolide anti-HIV agents: modification of the trans -10,11-dimethyldihydropyran-12-ol ring (ring C). J Med Chem 40:1005-1017.
31. Vink C, Oude Groeneger AM, Plasterk RH. 1993. Identification of the catalytic and DNA-binding region of the human immunodeficiency virus type I integrase protein. Nucleic Acids Res 21:1419-1425. http://dx.doi .org/10.1093/nar/21.6.1419.
32. Bushman FD, Engelman A, Palmer I, Wingfield P, Craigie R. 1993. Domains of the integrase protein of human immunodeficiency virus type 1 responsible for polynucleotidyl transfer and zinc binding. Proc Natl Acad Sci U S A 90:3428-3432. http://dx.doi.org/10.1073/pnas.90.8.3428.
33. Woerner AM, Marcus-Sekura CJ. 1993. Characterization of a DNA binding domain in the C-terminus of HIV-1 integrase by deletion mutagenesis. Nucleic Acids Res 21:3507-3511. http://dx.doi.org/10.1093/nar/21 .15.3507.
34. Engelman A, Hickman AB, Craigie R. 1994. The core and carboxylterminal domains of the integrase protein of human immunodeficiency virus type 1 each contribute to nonspecific DNA binding. J Virol 68:5911-5917.